For children with hemophilia A, the FDA has accepted the sBLA for ALTUVIIIO.

Published Date: 17 Sep 2023

The FDA has approved a supplemental biologics license application for ALTUVIIIO (Antihemophilic factor; Sanofi) for use in patients with severe hemophilia A who are 12 years of age or younger.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot